We found that the HDAC inhibitor CUDC-907 induced substantial tumor cell killing in all of 8 melanoma cell lines and exhibited additive (independent) to synergistic responses when combined with vemurafenib and trametinib in 6 cell lines (Fig. 3b, c). The gene discussed is HDAC9; the disease is melanoma.